Influence of MTHFR genotype on contingent negative variation and MRI abnormalities in migraine

Headache

Volumn 47, Issue 2, 2007, Pages 253-265

  De Tommaso, Marina ^a   Difruscolo, Olimpia ^a   Sardaro, Michele ^a   Losito, Luciana ^a   Serpino, Claudia ^a   Pietrapertosa, Anna ^a   Santeramo, Maria Teresa ^a   Dicuonzo, Franca ^a   Carella, Aristide ^a   Lamberti, Paolo ^a   Livrea, Paolo ^a  

^a UNIVERSITY OF BARI   (Italy)

Author keywords

Brain event related potentials; Homocysteine; Migraine; MRI

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); HOMOCYSTEINE;

ADULT; AGED; AMINO ACID BLOOD LEVEL; AMPLITUDE MODULATION; ARTICLE; BRAIN DAMAGE; CARDIOVASCULAR RISK; CASE CONTROL STUDY; CONTINGENT NEGATIVE VARIATION; CONTROLLED STUDY; ETHNIC GROUP; FEMALE; GENE FREQUENCY; GENETIC ANALYSIS; GENETIC CORRELATION; GENETIC PREDISPOSITION; GENETIC RISK; GENOTYPE; HABITUATION; HOMOZYGOSITY; HUMAN; HYPERHOMOCYSTEINEMIA; MAJOR CLINICAL STUDY; MALE; MIGRAINE; MIGRAINE WITHOUT AURA; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR; SAMPLE SIZE;

ADOLESCENT; ADULT; CASE-CONTROL STUDIES; CEREBROVASCULAR ACCIDENT; CONTINGENT NEGATIVE VARIATION; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HOMOCYSTEINE; HOMOZYGOTE; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; METHYLENETETRAHYDROFOLATE REDUCTASE (NADPH2); MIDDLE AGED; MIGRAINE DISORDERS; RISK FACTORS;

EID: 33846975109     PISSN: 00178748     EISSN: 15264610     Source Type: Journal    
DOI: 10.1111/j.1526-4610.2006.00690.x     Document Type: Article

References (45)

1. Goadsby PJ. Current concepts of the pathophysiology of migraine. Neurol Clin. 1997;15:27-42.
2. Russell MB. Genetic epidemiology of migraine and cluster headache. Cephalalgia. 1997;17:683-701.
3. Kors EE, Haan J, Ferrari MD. Genetics of primary headaches. Curr Opin Neurol. 1999;1:249-254.
4. Montagna P. Molecular genetics of migraine headaches: A review. Cephalalgia. 2000;20:3-14.
5. Ambrosini A, D'Onofrio M, Grieco GS, Di Mambro A, Montagna G, Fortini D, et al. Familial basilar migraine associated with a new mutation in the ATP1A 2 gene. Neurology. 2005;65:1826-1828.
6. Kowa H, Yasui K, Takeshima T, Urakami K, Sakai F, Nakashima K. The homozygous C677T mutation in the methylenetetrahydrofolate reductase gene is a genetic risk factor for migraine. Am J Med Genet. 2000;96:762-764.
7. Kara I, Sazci A, Ergul E, Kaya G, Kilic G. Association of the C677T and A1298C polymorphisms in the 5,10 methylenetetrahydrofolate reductase gene in patients with migraine risk. Brain Res Mol Brain Res. 2003;111:84-90.
8. Lea RA, Ovcaric M, Sundholm J, MacMillan J, Griffiths LR. The Methylenetetrahydrofolate reductase gene variant C677T influences susceptibility to migraine with aura. BMC Med. 2004;2:2-3.
9. Oterino A, Valle N, Bravo Y, Muñoz P, Sánchez-Velasco P, Ruiz-Alegría C, et al. MTHFR T677 homozygosis influences the presence of aura in migraineurs. Cephalalgia. 2004;24:491-494.
10. Scher AI, Terwindt GM, Verschuren WM, Kruit MC, Blom HJ, Kowa H, et al. Migraine and MTHFR C677T genotype in a population-based sample. Ann Neurol. 2006;59:372-375.
11. Dreier JP, Kleeberg J, Petzold G, Priller J, Windmuller O, Orzechowski HD, et al. Endothelin-1 potently induces Leao's cortical spreading depression in vivo in the rat: A model for an endothelial trigger of migrainous aura? Brain. 2002;125:102-112.
12. Hadjikhani N, Sanchez Del Rio M, Wu O, Schwartz D, Bakker D, Fischl B, et al. Mechanisms of migraine aura revealed by functional MRI in human visual cortex. Proc Natl Acad Sci U S A. 2001;98:4687-4692.
13. Obeid R, Herrmann W. Mechanisms of homocysteine neurotoxicity in neurodegenerative diseases with special reference to dementia. FEBS Lett. 2006;580:2994-3005.
14. Lipton SA, Kim WK, Choi YB, Kumar S, D'Emilia DM, Rayudu PV, et al. Neurotoxicity associated with dual actions of homocysteine at the N-methyl-D-aspartate receptor. Proc Natl Acad Sci U S A. 1997;94:5923-5928.
15. Kruman II, Culmsee C, Chan SL, Kruman Y, Guo Z, Penix L, et al. Homocysteine elicits a DNA damage response in neurons that promotes apoptosis and hypersensitivity to excitotoxicity. J Neurosci. 2000;20:6920-6926.
16. Ambrosini A, de Noordhout AM, Sandor PS, Schoenen J. Electrophysiological studies in migraine: A comprehensive review of their interest and limitations. Cephalalgia. 2003;23:13-31.
17. Schoenen J, Maertens de Noordhout A, Timsit-Berthier M, Timsit M. Contingent negative variation (CNV) as a diagnostic and physiopathologic tool in headache patients. In: Clifford Rose F, ed. Migraine: Clinical and Research Advances. Basel: Karger; 1985:17-25.
18. Kropp P, Kirbach U, Detlefsen JO, Siniatchkin M, Gerber WD, Stephani U. Slow cortical potentials in migraine: A comparison of adults and children. Cephalalgia. 1999;25:60-64.
19. Siniatchkin M, Kirsch E, Kropp P, Gerber WD, Stephani U. Contingent negative variation in migraine families. Cephalalgia. 2000;20:881-892.
20. Siniatchkin M, Kropp P, Gerber WD. Contingent negative variation in subjects at risk for migraine without aura. Pain. 2001;94:159-167.
21. Schoenen J, Timsit-Berthier M. Contingent negative variation: Methods and potential interest in headache. Cephalalgia. 1993;13:28-32.
22. Welch KMA. Contemporary concepts of migraine pathogenesis. Neurology. 2003;61:S2-S8.
23. Swartz RH, Kern RZ. Migraine is associated with magnetic resonance imaging white matter abnormalities: A meta-analysis. Arch Neurol. 2004;61:1366-1368.
24. Kruit MC, van Buchem MA, Hofman PA, Bakkers JT, Terwindt GM, Ferrari MD, et al. Migraine as a risk factor for subclinical brain lesions. JAMA. 2004;291:427-434.
25. Kruit MC, Launer LJ, Ferrari MD, van Buchem MA. Infarcts in the posterior circulation territory in migraine. The population-based MRI CAMERA study. Brain. 2005;128:2068-2077.
26. Wright CB, Paik MC, Brown TR, Stabler SP, Allen RH, Sacco RL, et al. Total homocysteine is associated with white matter hyperintensity volume: The Northern Manhattan Study. Stroke. 2005;36:1207-1211.
27. Headache Classification Committee. The International Classification of Headache Disorders II. Cephalalgia. 2004;24(suppl 1):24-136.
28. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders (DSM-IV), 4th ed. Washington DC: American Psychiatric Association; 1994.
29. D'Amico D, Mosconi P, Genco S, Usai S, Prudenzano AM, Grazzi L, et al. The Migraine Disability Assessment (MIDAS) questionnaire: Translation and reliability of the Italian version. Cephalalgia. 2001;21:947-952.
30. Böcker KBE, Timsit-Berthier M, Schoenen J, Brunia CHM. Contingent negative variation in migraine. Headache. 1990;30:604-609.
31. Petrinovich L, Widaman KF. An evaluation of statistical strategies to analyze repeated-measures data. In: Peeke HVS, Petrinovich L, eds. Habituation, Sensitization and Behavior. New York, NY: Academic Press; 1984:156-204.
32. Grandone E, Corrao AM, Colaizzo D, Vecchione G, Di Girgenti C, Paladini D, et al. Homocysteine metabolism in families from southern Italy with neural tube defects: Role of genetic and nutritional determinants. Prenat Diagn. 2006;26:1-5.
33. Rosenberg N, Murata M, Ikeda Y, Opare-Sem O, Zivelin A, Geffen E, et al. The frequent 5,10-methylenetetrahydrofolate reductase C677T polymorphism is associated with a common haplotype in whites, Japanese, and Africans. Am J Hum Genet. 2002;70:758-762.
34. Siniatchkin M, Averkina N, Gerber WD. Relationship between precipitating agents and neurophysiological abnormalities in migraine. Cephalalgia. 2006;26:457-465.
35. Do KQ, Herrling PL, Streit P, Turski WA, Cuenod M. In vitro release and electrophysiological effects in situ of homocysteic acid, an endogenous N-methyl-(D)-aspartic acid agonist, in themammalian striatum. J Neurosci. 1986;6:2226-2234.
36. Olney JW, Price MT, Salles KS, Labruyere J, Ryerson R, Mahan K, et al. Homocysteic acid: An endogenous excitotoxic ligand of the NMDA receptor. Brain Res. Bull. 1987;19:597-602.
37. Ito S, Provini L, Cherubini E. L-homocysteic acid mediates synaptic excitation at NMDA receptors in the hippocampus. Neurosci Lett. 1991;124:157-161.
38. Cuenod M., Do KQ, Streit P. Homocysteic acid as an endogenous excitatory amino acid. Trends Pharmacol Sci. 1990;11:477-478.
39. Longoni M, Ferrarese C. Inflammation and excitotoxicity: Role in migraine pathogenesis. Neurol Sci. 2006;27:S107-S110.
40. Welch KM. Contemporary concepts of migraine pathogenesis. Neurology. 2003;61(8 suppl 4):S2-S8.
41. Mongini F, Deregibus A, Rota E. Psychiatric disorders and muscle tenderness in episodic and chronic migraine. Expert Rev Neurother. 2005;5:635-642.
42. Swartz RH, Kern RZ. Migraine is associated with magnetic resonance imaging white matter abnormalities: A meta-analysis. Arch Neurol. 2004;61:1366-1368.
43. Schmidt R, Fazekas F, Kleinert G, Offenbacher H, Gindl K, Payer F, et al. Magnetic resonance imaging signal hyperintensities in the deep and subcortical white matter. A comparative study between stroke patients and normal volunteers. Arch Neurol. 1992;49:825-857.
44. Schoenen J, Lenaerts M, Bastings E. High-dose riboflavin as a prophylactic treatment of migraine: Results of an open pilot study. Cephalalgia. 1994;14:328-329.
45. Schoenen J, Jacquy J, Lenaerts M. Effectiveness of high-dose riboflavin in migraine prophylaxis. A randomized controlled trial. Neurology. 1998;50:466-470.